# Therapeutic Drug Monitoring in Epileptic Dogs: Antiepileptic Drug Levels


## Key Takeaways

- Therapeutic Drug Monitoring (TDM) in epileptic dogs is indicated for poor seizure control, suspected toxicity, or dose adjustments after pharmacokinetic changes, with sampling ideally at steady state (2-3 weeks post-dose change) and trough levels preferred for most antiepileptic drugs (AEDs).
- Established therapeutic ranges include phenobarbital (15-45 µg/mL), bromide (1000-2000 mg/L), and zonisamide (10-40 µg/mL), but these are population-derived guides, and individual patient response and adverse effects remain paramount clinical endpoints.
- Free phenobarbital levels are critical in hypoalbuminemic or uremic dogs, as total levels may be misleading due to altered protein binding, necessitating specific requests for free drug assays or cautious interpretation.
- Levetiracetam possesses a wide therapeutic index, and TDM is primarily used to confirm absorption or adherence rather than to avoid toxicity, with monitoring less established compared to phenobarbital or bromide.
- Serial TDM results, documented with dose, interval, sampling time, concentration, reference range, and clinical status, are essential for trend recognition and detecting pharmacokinetic instability or clinical misalignment before adverse events manifest.
- Common errors include sampling before steady state, interpreting single concentrations in isolation, adjusting doses solely on lab values without clinical reassessment, and failing to account for drug interactions, all requiring careful documentation and repeat sampling for correction.

---

Therapeutic drug monitoring (TDM) in canine epilepsy refers to the measurement of antiepileptic drug (AED) concentrations in serum or plasma to guide dosing, assess adherence, and reduce the risk of toxicity. This article addresses the practicing veterinarian who manages dogs with recurrent seizures and needs a practical framework for when to measure drug levels, how to interpret the results, and what actions follow from specific findings. The scope is limited to AEDs used in canine epilepsy, principally phenobarbital, bromide, and the newer agents such as zonisamide and levetiracetam. The procedural focus distinguishes this reference from general pharmacology reviews: the emphasis is on decision criteria, sampling timing, and interpretation logic instead of on drug mechanisms alone.

The clinical question this article answers is direct: given a dog with seizures, when does a serum drug level change management, and how should the clinician act on the number reported by the laboratory? The answer requires an understanding of pharmacokinetic principles, the therapeutic ranges established for each drug, and the limitations of those ranges in individual patients. Seizure control and adverse effects remain the primary endpoints of therapy, drug levels are a surrogate that supports, but does not replace, clinical judgment.

## At a Glance

| Parameter | Clinical Decision Point |
|---|---|
| Primary indication for TDM | Poor seizure control despite appropriate dosing, suspected toxicity, or dose adjustment after pharmacokinetic changes |
| Sampling time | Steady state, typically 2 to 3 weeks after starting or changing a phenobarbital dose, trough levels preferred for most AEDs |
| Phenobarbital therapeutic range | 15 to 45 µg/mL in dogs, with individual variation in response and toxicity |
| Bromide therapeutic range | 1000 to 2000 mg/L (1.0 to 2.0 g/L), often used with phenobarbital |
| Zonisamide therapeutic range | 10 to 40 µg/mL, with limited evidence for a precise toxic threshold in dogs |
| Levetiracetam | Wide therapeutic index, TDM used mainly to document absorption or adherence, not to avoid toxicity |
| Free versus total drug levels | Free phenobarbital levels matter in hypoalbuminemia or uremia, total levels may mislead |
| Frequency of monitoring | At steady state after dose changes, then every 6 to 12 months in stable dogs, and whenever seizures recur or adverse effects appear |

## Pharmacokinetic Basis for Monitoring

The rationale for TDM rests on predictable relationships between dose, serum concentration, and effect. For phenobarbital, the drug has a long elimination half-life in dogs, approximately 40 to 90 hours, which produces relatively stable serum concentrations once steady state is reached. This stability makes a single trough sample reasonably representative of the average exposure over the dosing interval. The same logic applies to bromide, which has an elimination half-life measured in days, and to zonisamide, which has a half-life of roughly 15 to 20 hours in dogs.

The relationship between serum concentration and clinical effect is not identical across AEDs. Phenobarbital has a well-characterized concentration-response curve in dogs, with most animals achieving seizure control within the accepted therapeutic range and toxicity becoming more likely above it. Zonisamide, by contrast, has a less firmly established range in dogs, and the evidence base derives substantially from human studies and experimental models. A review of zonisamide's pharmacodynamic and pharmacokinetic properties noted that clinical trials in humans documented efficacy across several seizure types, but the precise concentration thresholds for effect and toxicity in dogs remain extrapolated. This distinction matters clinically: the veterinarian should treat the published range for zonisamide as a guide, not a rule, and should weight seizure frequency and adverse effects more heavily than the laboratory value.

## The Concept of Therapeutic Range

A therapeutic range is a population-derived interval that describes the serum concentrations associated with maximum efficacy and minimum toxicity in the majority of patients. It is not a biological boundary. Individual dogs may achieve excellent seizure control below the lower limit of the range, and others may tolerate concentrations above the upper limit without adverse effects. The range serves as a starting point for interpretation, not a target that overrides clinical observation.

For phenobarbital, the commonly cited range of 15 to 45 µg/mL reflects decades of clinical experience and is supported by veterinary reference sources. Concentrations below 15 µg/mL are frequently associated with inadequate seizure control, although some dogs, particularly those with mild or infrequent seizures, may respond at lower levels. Concentrations above 45 µg/mL increase the risk of sedation, ataxia, polyphagia, and hepatopathy, but the threshold for toxicity varies with individual susceptibility and duration of exposure.

Bromide presents a different interpretive challenge. The drug is eliminated largely unchanged by the kidney, and its half-life is long enough that steady state may require weeks to months to achieve. The therapeutic range of 1000 to 2000 mg/L is used in combination therapy with phenobarbital, and some clinicians target higher levels when bromide is used as monotherapy. Because bromide competes with chloride for renal reabsorption, changes in dietary salt intake can alter serum concentrations, and TDM is particularly useful when a dog's diet changes or when renal function fluctuates.

## Free Drug Concentrations and Protein Binding

Phenobarbital is approximately 40% to 50% protein bound in dogs, which means that total serum concentrations generally reflect free drug levels adequately in healthy animals. However, conditions that lower serum albumin, such as hepatic insufficiency, protein-losing enteropathy, or malnutrition, increase the free fraction. In these circumstances, a total phenobarbital level within the therapeutic range may correspond to a free concentration that is toxic. Conversely, uremia can displace phenobarbital from binding sites, producing a similar discrepancy. When such comorbidities are present, the clinician should request a free phenobarbital level or interpret the total level with caution.

Zonisamide is more extensively protein bound, and its binding is saturable at higher concentrations. This nonlinearity complicates interpretation of total levels, particularly at the upper end of the dosing range. The practical consequence is that dose adjustments based on total zonisamide levels should be made incrementally, with clinical response and adverse effects given at least equal weight to the laboratory value.

## Study Design Logic and Evidence Limitations

The evidence supporting TDM in canine epilepsy is largely observational and extrapolated from human medicine. Controlled trials that randomize dogs to TDM-guided versus clinically guided dosing are scarce, and the therapeutic ranges in use have not been validated in large prospective canine studies. The kindling model of epilepsy, which has been used to assess AED efficacy in experimental settings, highlighted the importance of monitoring plasma drug levels during drug assessment, but this model does not directly establish clinical ranges for dogs. Similarly, work on epileptogenesis in animal models has clarified the biological processes that lead to recurrent seizures, but it does not provide concentration targets for clinical monitoring.

This evidence base has practical implications. The veterinarian should treat published ranges as reference intervals derived from mixed sources, apply them with attention to the individual patient, and document the clinical response alongside the laboratory value. When a dog is well controlled at a concentration outside the published range, the clinical outcome takes precedence. When a dog is poorly controlled at a concentration within the range, the clinician should consider whether the range applies to this patient, whether drug interactions are altering free levels, and whether the diagnosis of epilepsy itself is correct.

## Indications for Therapeutic Drug Monitoring

Therapeutic drug monitoring (TDM) is not required for every epileptic dog receiving antiepileptic drugs. The decision to measure serum drug concentrations should be driven by specific clinical circumstances. Routine monitoring is indicated when treatment is initiated, when the drug dose is changed, when seizure control is inadequate, when adverse effects are suspected, and when drug interactions may alter clearance. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) provides regulatory context for approved drug use, but the clinical decision to monitor rests on patient-specific factors.

Monitoring at steady state after dose initiation or adjustment is the most common indication. Steady state is reached after approximately five half-lives. For phenobarbital in dogs, this typically occurs 10 to 14 days after starting therapy or changing the dose. Sampling before this point produces concentrations that do not reflect the eventual steady-state value and may lead to inappropriate dose adjustments.

TDM is also indicated when seizure frequency increases despite apparent compliance. A subtherapeutic concentration confirms inadequate drug exposure. A therapeutic concentration with breakthrough seizures suggests drug resistance or progressive brain disease instead of underdosing. In this setting, the clinician must decide whether to push the drug toward the upper end of the therapeutic range, add a second agent, or pursue advanced diagnostics such as intracranial imaging. [Neuronuclear assessment techniques](https://pubmed.ncbi.nlm.nih.gov/18514079/) may be relevant in refractory cases where structural or functional imaging could identify a surgical target.

Monitoring is appropriate when clinical signs of toxicity appear. Phenobarbital toxicity produces sedation, ataxia, polyphagia, and polyuria. These signs overlap with the expected dose-dependent effects seen during the first weeks of therapy, so a measured concentration helps distinguish transient adaptation from true accumulation. Zonisamide toxicity is less well characterized in dogs, but sedation and gastrointestinal signs have been reported. The [review of zonisamide pharmacology](https://pubmed.ncbi.nlm.nih.gov/7686468/) notes that the drug has a more favourable therapeutic index than many other antiepileptic drugs in animal models, but clinical tolerability advantages have not been consistently confirmed.

## Sampling Protocols and Timing

Sample timing depends on the drug and the question being asked. For phenobarbital, trough concentrations are preferred. A trough sample is collected immediately before the next scheduled dose. This reflects the lowest concentration the dog experiences during the dosing interval and is the most reproducible point for comparison across visits. Peak concentrations add little clinical information for phenobarbital because the drug has a long half-life and the peak-to-trough fluctuation is modest.

For zonisamide, the longer half-life in dogs means that timing is less critical. A sample collected at any point in the dosing interval provides a clinically useful estimate of steady-state exposure, provided the dog has been on a stable dose for at least two weeks. Consistency in sampling time across serial measurements is still recommended to reduce interpretive error.

The table below summarizes target ranges and sampling guidance for the antiepileptic drugs most commonly monitored in canine practice. These ranges are derived from clinical experience and published reference data. Individual dogs may achieve excellent seizure control below the lower limit or show toxicity within the range, so the numbers are guides, not absolute thresholds.

| Drug | Target range | Sampling time | Steady state | Notes |
|------|-------------|---------------|--------------|-------|
| Phenobarbital | 15 to 45 µg/mL (65 to 195 µmol/L) | Trough, immediately before next dose | 10 to 14 days | Many dogs are controlled at 20 to 35 µg/mL, toxicity more likely above 40 µg/mL |
| Potassium bromide | 1000 to 2000 mg/L (10 to 20 mmol/L) | Trough, before next dose | 60 to 90 days | Long half-life, monitor 3 months after dose change |
| Zonisamide | 10 to 40 µg/mL | Any point in dosing interval | 5 to 7 days | Target range extrapolated from human data, canine data limited |
| Levetiracetam | 5 to 45 µg/mL | Trough, 1 to 2 hours before next dose | 1 to 2 days | Immediate-release formulation requires frequent dosing, monitoring less established |

Potassium bromide is included because it is frequently used as an adjunct in dogs with refractory seizures. Its very long half-life means that steady state is not reached for two to three months. Sampling earlier than this will show a concentration that is still rising, and dose adjustments based on such samples risk overshooting the target.

## Interpretation of Subtherapeutic Concentrations

A measured concentration below the target range has several possible explanations. The most common is non-adherence, either because the owner has missed doses or because the dog has vomited a dose. Asking about recent gastrointestinal signs and observed dosing is the first step. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides general guidance on antiepileptic drug use and adverse effect recognition that supports this history-taking approach.

Malabsorption is uncommon in dogs but can occur with concurrent gastrointestinal disease. Drug interactions are a more frequent cause of subtherapeutic concentrations. Phenobarbital induces hepatic enzymes and increases the clearance of many drugs, including other antiepileptics. When a second drug is added, the phenobarbital concentration may fall as its own metabolism is induced. Rechecking concentrations two weeks after any change in the antiepileptic drug regimen is a practical safeguard.

Rapid clearance is an individual pharmacokinetic trait. Some dogs metabolise phenobarbital quickly and require higher maintenance doses to sustain a therapeutic trough. In these dogs, the dose interval may need to be shortened instead of simply increasing the dose, although twice-daily dosing is usually sufficient. The [early work on drug monitoring in kindling models](https://pubmed.ncbi.nlm.nih.gov/406881/) emphasized that plasma level monitoring is essential to interpret drug effects in experimental epilepsy research, and the same principle applies clinically: without a measured concentration, the clinician cannot distinguish rapid clearance from poor absorption from non-adherence.

## Interpretation of Toxic Concentrations

Concentrations above the target range require a different decision pathway. The first question is whether the dog is showing clinical signs of toxicity. If the dog is sedated and ataxic with a phenobarbital concentration of 50 µg/mL, the dose should be reduced. If the dog is asymptomatic with the same concentration, the clinician must weigh the risk of delayed toxicity against the benefit of continued seizure control. A gradual dose reduction with rechecking in two weeks is a reasonable approach.

Toxic concentrations can also result from drug interactions. Adding an inhibitor of hepatic metabolism can raise phenobarbital concentrations. Chloramphenicol is a well-known example, although it is rarely used in dogs today. More relevant in current practice is the addition of other anticonvulsants that compete for metabolic pathways. The [review of zonisamide pharmacology](https://pubmed.ncbi.nlm.nih.gov/7686468/) notes that zonisamide has a favourable therapeutic index in animal models, but this does not eliminate the need for monitoring when it is combined with other drugs.

When toxicity is confirmed by both clinical signs and laboratory values, the dose should be reduced by 10 to 25 percent and the concentration rechecked at the new steady state. Rapid reduction can precipitate withdrawal seizures, so gradual adjustment is preferred unless the dog is severely affected. Hospitalization and supportive care are indicated for marked toxicity with obtundation or respiratory depression.

## Troubleshooting Guide

The following table provides a structured approach to common monitoring scenarios. The clinician should use this as a framework, not a protocol, and adapt it to the individual patient.

| Scenario | Likely cause | Action |
|----------|-------------|--------|
| Low concentration, seizures controlled | Dose too low for this dog, or sample taken before steady state | Recheck at steady state, if still low, increase dose and recheck |
| Low concentration, seizures uncontrolled | Non-adherence, malabsorption, rapid clearance, or drug interaction | Verify dosing history, check for vomiting, consider interaction, increase dose |
| Therapeutic concentration, seizures uncontrolled | Drug resistance, progressive disease, or wrong drug for seizure type | Consider add-on therapy, reassess diagnosis, consider imaging |
| High concentration, no clinical signs | Sample timing error, or dog tolerates high level | Confirm timing, monitor clinically, consider gradual dose reduction |
| High concentration, clinical signs of toxicity | Dose too high, accumulation, or interaction | Reduce dose 10 to 25 percent, recheck at steady state, supportive care if severe |
| Concentration changed without dose change | Drug interaction, hepatic disease, or laboratory error | Review all medications, assess liver function, repeat sample |

## Documentation and Longitudinal Tracking

Serial TDM results should be recorded in a consistent format that allows trend recognition. The record should include the drug, dose in mg/kg, dosing interval, sampling time relative to the last dose, the measured concentration, the laboratory reference range, and the clinical status at the time of sampling. Seizure frequency and adverse effects should be documented at each visit so that concentration data can be interpreted in context.

A single concentration is a snapshot. The value of TDM increases with repeated measurements over time. A dog that was stable on phenobarbital for two years with a concentration of 25 µg/mL may develop a rising concentration without a dose change if hepatic disease develops. Serial monitoring detects this trend before clinical toxicity appears. Conversely, a falling concentration in a dog with good seizure control may signal the need for a dose increase before breakthrough seizures occur.

Laboratory variability is a real consideration. Different assays and different laboratories can produce different results for the same sample. When trends are being followed, the same laboratory should be used consistently. If the laboratory changes, a repeat sample should be analyzed by the new laboratory before any dose adjustment is made.

## Recognized Complications and Early Detection

The principal complications of antiepileptic drug monitoring in dogs fall into three categories: laboratory error, pharmacokinetic instability, and clinical misalignment between drug concentration and therapeutic effect.

Laboratory error is detected by comparing paired samples. A common practice is to submit duplicate aliquots from the same venipuncture under different identifiers. Discordance beyond the laboratory's stated coefficient of variation, typically 5 to 10 percent for immunoassay methods, signals a processing problem. Hemolysis, lipaemia, and delayed serum separation can each alter measured concentrations, particularly for enzyme-multiplied immunoassay techniques. The clinician should confirm the laboratory's validation species. Assays calibrated for human matrix may perform acceptably for phenobarbital but can be unreliable for other compounds.

Pharmacokinetic instability arises from changes in hepatic enzyme induction, protein binding, or gastrointestinal absorption. Phenobarbital induces its own metabolism over the first two to four weeks of therapy, so a concentration measured at steady state on day 14 may drift downward by day 30 despite an unchanged dose. A second steady-state sample at four to six weeks is the discriminating check. For highly protein-bound drugs, a low total concentration with adequate free fraction can occur in hypoalbuminaemic patients, and the reverse is possible in inflammatory states. If clinical response does not match the total concentration, request a free drug measurement or reassess the patient's albumin status.

Clinical misalignment is the most consequential failure mode. A dog with controlled seizures and a concentration below the reference interval does not require a dose increase. Conversely, a dog with persistent seizures and a concentration within the reference interval may still benefit from escalation. The therapeutic range is a population-derived guide, not a biological law. The kindling model literature has long emphasized that plasma level monitoring is desirable for interpreting drug effects, but the same literature cautions that individual response varies with the epileptogenic insult and the brain site involved [Wada's review of pharmacological prophylaxis in the kindling model](https://pubmed.ncbi.nlm.nih.gov/406881/).

## Common Errors and Corrective Action

Less experienced clinicians frequently sample too early. Drawing a trough concentration before steady state has been reached, typically five half-lives after initiation or a dose change, produces a falsely low value that invites an unnecessary dose increase. The corrective action is to calculate the expected time to steady state from the drug's half-life and to document the sampling date relative to the last dose change.

A second error is interpreting a single concentration in isolation. A single value cannot distinguish a genuine subtherapeutic state from a sampling artefact, a missed dose, or a laboratory issue. Repeat sampling with a documented dosing history is the corrective step.

A third error is adjusting dose on the basis of concentration alone without reassessing seizure frequency and adverse effects. The monitoring result should be integrated with the owner's seizure diary and the physical examination. The [MSD Veterinary Manual professional edition](https://www.msdvetmanual.com/) provides species-specific pharmacology guidance that supports this integrated approach.

A fourth error is failing to account for drug interactions. Concurrent administration of other enzyme-inducing or enzyme-inhibiting drugs can shift concentrations unpredictably. When a second drug is added or withdrawn, repeat monitoring after the new steady state is reached.

## Limitations of the Evidence and Divergent Expert Opinion

The evidence base for therapeutic ranges in canine epilepsy is largely extrapolated from human medicine and from experimental models. The kindling model has been proposed as a bridge between standard screening tests and clinical practice, but standardization of techniques and cross-species validation remain incomplete [Wada's review of pharmacological prophylaxis in the kindling model](https://pubmed.ncbi.nlm.nih.gov/406881/). Studies of epileptogenesis in animal models have identified age-specific mechanisms and developmental regulation of seizure susceptibility, which raises the question of whether adult canine reference intervals apply to juvenile dogs [Rakhade and Jensen on epileptogenesis in the immature brain](https://pubmed.ncbi.nlm.nih.gov/19578345/).

Expert opinion diverges on the frequency of monitoring in well-controlled dogs. Some clinicians recheck concentrations every six to twelve months, others monitor only after dose changes or clinical events. There is no controlled trial in dogs that establishes a superior interval. Similarly, the value of monitoring newer antiepileptic drugs such as zonisamide is debated. Clinical experience with zonisamide in human patients has documented efficacy across several seizure types, but the relationship between serum concentration and response in dogs is less firmly established than for phenobarbital [Peters and Sorkin on zonisamide](https://pubmed.ncbi.nlm.nih.gov/7686468/).

## Referral, Consultation, and Reporting

Referral to a veterinary neurologist is warranted when seizures persist despite a documented therapeutic concentration, when adverse effects limit dose escalation, when the seizure semiology changes, or when the clinician suspects a progressive intracranial lesion. Specialist evaluation may include advanced imaging, electroencephalography, or cerebrospinal fluid analysis, none of which are replaced by drug monitoring.

Laboratory consultation is appropriate when results do not match clinical expectations, when assay interference is suspected, or when free drug measurement is required. The laboratory should be asked about its assay platform, validation species, and reference interval derivation.

Regulatory reporting obligations are limited in companion animal practice. Adverse drug events associated with approved products may be reported to the FDA Center for Veterinary Medicine, which maintains the animal drug information and adverse event reporting system [FDA Center for Veterinary Medicine animal drug information](https://www.fda.gov/animal-veterinary). Reporting is voluntary but contributes to pharmacovigilance. The AVMA practice resources provide guidance on professional obligations and documentation standards [AVMA practice resources](https://www.avma.org/resources-tools).

| Observation | Likely cause | Discriminating check |
| --- | --- | --- |
| Low trough, good seizure control | Sampling before steady state | Confirm time since last dose change |
| Low trough, poor seizure control | Inadequate dose or poor absorption | Repeat sample, review dosing history |
| High trough, no adverse effects | Protein binding shift or assay issue | Free drug measurement, duplicate sample |
| High trough, sedation or ataxia | True toxicity | Reduce dose, recheck in 5 half-lives |
| Concentration falls after dose increase | Enzyme induction | Recheck at 4 to 6 weeks after change |
| Discordant duplicate samples | Laboratory error | Contact laboratory, request repeat analysis |

## Frequently Asked Questions

### How Often Should Antiepileptic Drug Concentrations Be Rechecked in a Seizure-Free Dog?

For a dog with well-controlled seizures and stable drug concentrations, rechecking every 6 to 12 months is reasonable. More frequent monitoring is warranted after any dose adjustment, addition or removal of a concurrent medication, or a change in formulation or manufacturer. A single trough concentration measured 2 weeks after a dose change allows confirmation of steady state. Annual measurement also provides a baseline against which future changes can be interpreted. If the dog develops new clinical signs, suspected toxicity, or an unexplained deterioration in seizure control, an immediate measurement is indicated instead of waiting for the scheduled recheck. Reference ranges should be interpreted in the context of the individual patient's clinical response.

### What Can Be Done When the Laboratory Turnaround Time Delays Clinical Decisions?

When results are not available for several days, the clinician must rely on clinical judgment. If the dog is actively seizing, the priority is to stabilize the patient with appropriate emergency therapy while awaiting the drug concentration. For a dog with suspected toxicity, dose reduction can be guided by the severity of clinical signs, with the caveat that the dose may need further adjustment once the concentration is known. Many commercial laboratories offer expedited processing for urgent samples. Point-of-care analyzers for phenobarbital are available in some referral settings and can provide results within minutes. When using these devices, confirmatory testing through a reference laboratory is prudent for critical decisions, as method-specific variability exists.

### How Do Monitoring Practices Differ Between Phenobarbital and Newer Antiepileptic Drugs?

Phenobarbital has a well-established therapeutic range, predictable pharmacokinetics, and a strong correlation between serum concentration and both efficacy and toxicity. Monitoring is therefore routine and widely available. For newer agents such as zonisamide, the evidence base for a defined therapeutic range is less robust, and the correlation between concentration and clinical effect is less clearly established. Human-derived ranges are often extrapolated to dogs, which introduces uncertainty given species differences in metabolism and protein binding. Measurement of these drugs is also less readily available and more costly. For these reasons, monitoring of newer agents is typically reserved for cases of inadequate response, suspected toxicity, or suspected poor owner compliance, instead of performed routinely.

### What Are the Practical Options When an Owner Cannot Afford Drug Concentration Testing?

When cost is prohibitive, the clinician should prioritize clinical monitoring. Seizure frequency, severity, duration, and adverse effects should be documented systematically at each visit. The physical examination, particularly for signs of sedation, ataxia, or hepatopathy, provides useful indirect information. Baseline hematology and serum biochemistry, especially liver enzyme activity and albumin concentration, can be performed at lower cost than drug assays and help detect certain adverse effects. The owner should understand that empirical dose adjustment carries a higher risk of undertreatment or toxicity. A staged approach can be used, with drug concentration measurement reserved for situations where clinical assessment is ambiguous, such as breakthrough seizures without obvious cause or suspected toxicity with an unremarkable examination.

### How Should Drug Concentrations Be Interpreted in a Dog with Concurrent Hepatic Disease?

Phenobarbital is extensively metabolised by the liver, and hepatic dysfunction can prolong its elimination half-life. A given dose may therefore produce higher steady-state concentrations than expected. Conversely, chronic phenobarbital administration induces hepatic enzymes, which can complicate interpretation of liver enzyme activity on biochemistry panels. In a dog with hepatic disease, the therapeutic target should be the lowest concentration that controls seizures without unacceptable adverse effects, instead of a fixed population-based range. More frequent monitoring is advisable, and dose adjustments should be smaller and followed by repeat measurement after a longer interval to allow steady state. The clinician should also consider whether the hepatic disease itself, or concurrent medications, may be altering protein binding and thus the free drug fraction.

### What Information Should Be Included When Requesting a Drug Concentration Measurement?

The laboratory request should include the drug name, the time of the last dose, the time of sample collection, the current dose and dosing interval, and the dog's body weight. The clinician should also note the indication for monitoring, such as routine surveillance, suspected toxicity, or breakthrough seizures. This information allows the laboratory to flag potentially toxic concentrations and assists the clinician in interpreting the result. The sample should be collected as a trough, immediately before the next dose, unless a peak concentration is specifically required. Serum or plasma should be separated promptly and stored according to the laboratory's specifications. Clear documentation in the medical record of the sampling time relative to dosing is essential for meaningful longitudinal comparison.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Pharmacological prophylaxis in the kindling model of epilepsy.](https://pubmed.ncbi.nlm.nih.gov/406881/). 1977.
- [Therapeutic approaches to epileptogenesis--hope on the horizon.](https://pubmed.ncbi.nlm.nih.gov/20618393/). 2010.
- [Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.](https://pubmed.ncbi.nlm.nih.gov/7686468/). 1993.
- [Epileptogenesis in the immature brain: emerging mechanisms.](https://pubmed.ncbi.nlm.nih.gov/19578345/). 2009.
- [From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options.](https://pubmed.ncbi.nlm.nih.gov/19187291/). 2009.
- [Neuronuclear assessment of patients with epilepsy.](https://pubmed.ncbi.nlm.nih.gov/18514079/). 2008.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Therapeutic Drug Monitoring of Aminoglycosides in Veterinary Patients: Indications and Protocols](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-aminoglycosides)
- [Therapeutic Drug Monitoring of Cyclosporine in Veterinary Dermatology: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-cyclosporine)
- [Therapeutic Drug Monitoring in Veterinary Practice: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-veterinary-practice-indications-interpretation)
- [Therapeutic Drug Monitoring of Digoxin in Canine Cardiac Disease: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-digoxin-canine)
- [Drug Interactions with Antidiabetic Medications in Dogs and Cats](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antidiabetic-medications-dogs-cats)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.